Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

2POPLAR, 2016 OAK (all population), 20161CheckMate 078, 20191JAVELIN Lung 200 (all population), 2018atezolizumab alone vs. avelumab alone 0.88 [0.70; 1.09]0.88 [0.70;1.09]atezolizumab alone vs. avelumab alone 0.88 [0.70; 1.09]atezolizumab alone vs. docetaxel atezolizumab alone better 0.79 [0.70; 0.89]0.79 [0.70;0.89]atezolizumab alone vs. docetaxel atezolizumab alone better 0.79 [0.70; 0.89]atezolizumab alone vs. nivolumab alone 1.16 [0.86; 1.57]1.16 [0.86;1.57]atezolizumab alone vs. nivolumab alone 1.16 [0.86; 1.57]avelumab alone vs. atezolizumab alone 1.14 [0.92; 1.42]1.14 [0.92;1.42]avelumab alone vs. atezolizumab alone 1.14 [0.92; 1.42]avelumab alone vs. docetaxel 0.90 [0.75; 1.08]0.90 [0.75;1.08]avelumab alone vs. docetaxel 0.90 [0.75; 1.08]avelumab alone vs. nivolumab alone 1.32 [0.95; 1.84]1.32 [0.95;1.84]avelumab alone vs. nivolumab alone 1.32 [0.95; 1.84]docetaxel vs. atezolizumab alone atezolizumab alone better 1.27 [1.12; 1.44]1.27 [1.12;1.44]docetaxel vs. atezolizumab alone atezolizumab alone better 1.27 [1.12; 1.44]docetaxel vs. avelumab alone 1.11 [0.93; 1.33]1.11 [0.93;1.33]docetaxel vs. avelumab alone 1.11 [0.93; 1.33]docetaxel vs. nivolumab alone nivolumab alone better 1.47 [1.12; 1.93]1.47 [1.12;1.93]docetaxel vs. nivolumab alone nivolumab alone better 1.47 [1.12; 1.93]nivolumab alone vs. atezolizumab alone 0.86 [0.64; 1.17]0.86 [0.64;1.17]nivolumab alone vs. atezolizumab alone 0.86 [0.64; 1.17]nivolumab alone vs. avelumab alone 0.76 [0.54; 1.05]0.76 [0.54;1.05]nivolumab alone vs. avelumab alone 0.76 [0.54; 1.05]nivolumab alone vs. docetaxel nivolumab alone better 0.68 [0.52; 0.89]0.68 [0.52;0.89]nivolumab alone vs. docetaxel nivolumab alone better 0.68 [0.52; 0.89]docetaxelatezolizumab alonenivolumab aloneavelumab aloneTislelizumabdirect evidencenetwork meta-analysis
T vs. C docetaxelatezolizumab alonenivolumab aloneavelumab aloneTislelizumab
docetaxel---1.27
1.12; 1.44		1.47
1.12; 1.93		1.11
0.93; 1.33		NA
atezolizumab alone0.79
0.70; 0.89		---1.16
0.86; 1.57		0.88
0.70; 1.09		NA
nivolumab alone0.68
0.52; 0.89		0.86
0.64; 1.17		---0.76
0.54; 1.05		NA
avelumab alone0.90
0.75; 1.08		1.14
0.92; 1.42		1.32
0.95; 1.84		---NA
TislelizumabNANANANA---

pathologies: 37 - treatments: 940 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons